These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9453967)

  • 1. [Increased CK in lipid-lowering therapy].
    Assmann G
    Internist (Berl); 1997 Nov; 38(11):1114. PubMed ID: 9453967
    [No Abstract]   [Full Text] [Related]  

  • 2. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering therapy--benefits and risks.
    Shechter M
    Isr Med Assoc J; 2007 Feb; 9(2):133; author reply 133-4. PubMed ID: 17348492
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid-lowering therapy--benefits and risks.
    Abinader EG
    Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
    [No Abstract]   [Full Text] [Related]  

  • 5. [Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
    Galiana J; Marchán E; Montés I; Pato S
    Rev Clin Esp; 1995 Sep; 195(9):620-2. PubMed ID: 7481005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings.
    Mosshammer D; Lorenz G; Meznaric S; Schwarz J; Muche R; Mörike K
    Fam Pract; 2009 Apr; 26(2):88-95. PubMed ID: 19233960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract]   [Full Text] [Related]  

  • 8. Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
    Aronow HD; Lincoff AM; Quinn MJ; McRae AT; Gurm HS; Houghtaling PL; Granger CB; Harrington RA; Van de Werf F; Topol EJ; Lauer MS;
    Am J Cardiol; 2008 Nov; 102(9):1119-24. PubMed ID: 18940276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Striated muscular injury and myocardiac injury caused by acute carbon monoxide poisoning].
    Wang HT; Xu XX; Li YP
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Dec; 23(6):435-7. PubMed ID: 16405777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation.
    Wu AH; Smith A; Wians F
    Clin Chim Acta; 2009 Jan; 399(1-2):109-11. PubMed ID: 18848535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of combining theophylline and drugs that potentially elevate serum creatine kinase.
    Iwano J; Nakamura Y; Izumida T; Yokota M; Takiguchi Y; Minakuchi K; Sone S
    J Med Invest; 2000 Feb; 47(1-2):9-13. PubMed ID: 10740974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic risk factors associated with lipid-lowering drug-induced myopathies.
    Vladutiu GD; Simmons Z; Isackson PJ; Tarnopolsky M; Peltier WL; Barboi AC; Sripathi N; Wortmann RL; Phillips PS
    Muscle Nerve; 2006 Aug; 34(2):153-62. PubMed ID: 16671104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    Jones PH
    Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of serum creatine kinase elevation and its relation to medications used after heart transplantation.
    Hsu RB; Chen RJ; Wang SS; Chu SH
    Clin Transplant; 2005 Feb; 19(1):45-50. PubMed ID: 15659133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing statin myopathy.
    Venero CV; Thompson PD
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):121-36. PubMed ID: 19217515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antilipemic therapy and rhabdomyolysis].
    Paragh G; Balogh Z; Romics L
    Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
    McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
    J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myopathy associated with statin therapy.
    Hilton-Jones D
    Neuromuscul Disord; 2008 Jan; 18(1):97-8. PubMed ID: 17892936
    [No Abstract]   [Full Text] [Related]  

  • 19. Fenofibrate-induced myopathy.
    Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
    Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experts confirm statins' safety but advise caution with certain patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(13):1-2, 5. PubMed ID: 12515256
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.